Analysts anticipate a Q3 2026 net loss of $0.38 per share on zero revenue, while the stock currently trades at $10.68—well below the average analyst price target of $21.71.
The central focus for investors is the upcoming registrational update for DT-216P2, the company's lead GeneTAC candidate for Friedreich ataxia. Building on positive four-week clinical results showing increased frataxin mRNA levels, the market is now seeking confirmation of sustained efficacy in longer-term trials. Design Therapeutics maintains a strong cash position exceeding $200 million, providing a financial runway through 2029 for its clinical proof-of-concept milestones.